Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CAMPATH: from concept to clinic.

Herman Waldmann1, Geoff Hale

  • 1Sir William Dunn School of Pathology, University of Oxford, UK. herman.waldmann@path.ox.ac.uk

Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
|September 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase 1 experimental medicine study of anti-CD3 monoclonal antibody in rheumatoid arthritis.

Immunotherapy advances·2025
Same author

Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors.

mAbs·2024
Same author

Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors.

mAbs·2024
Same author

Living in LALA land? Forty years of attenuating Fc effector functions.

Immunological reviews·2024
Same author

Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names.

mAbs·2022
Same author

Dry-compression packing of hydroxyapatite nanoparticles within a flat cuboid chromatography device and its use for fast protein separation.

Journal of chromatography. A·2022

Alemtuzumab, a lymphocyte-depleting therapy, shows long-term benefits for autoimmune diseases. This immunosuppressive drug may enable reduced medication in transplantation and autoimmune conditions by promoting tolerance.

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation medicine

Background:

  • Lymphocyte depletion is a key immunosuppressive strategy.
  • Alemtuzumab (CAMPATH-1H) was developed as an alternative to anti-lymphocyte globulins for transplantation.
  • Alemtuzumab is approved for chronic lymphocytic leukemia and shows promise in autoimmune diseases.

Purpose of the Study:

  • To evaluate the potential of alemtuzumab in facilitating tolerance.
  • To explore alemtuzumab's role in drug minimization for various immune-mediated conditions.

Main Methods:

  • Utilized alemtuzumab (CAMPATH-1H) for lymphocyte depletion therapy.
  • Assessed short-term therapy outcomes for long-term benefits.

Main Results:

Related Experiment Videos

  • Alemtuzumab demonstrated efficacy in lymphocyte depletion.
  • Short-term alemtuzumab treatment yielded long-term benefits in autoimmune conditions.
  • The drug shows potential for inducing tolerance.

Conclusions:

  • Alemtuzumab is an effective immunosuppressive agent with established use in leukemia.
  • Short-term alemtuzumab therapy offers long-term advantages in autoimmune diseases.
  • Alemtuzumab may facilitate tolerance, enabling reduced immunosuppression in transplantation and autoimmune disorders.